# Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

> **NCT03410108** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 104 (actual)

## Conditions studied

- ALK-positive Advanced NSCLC

## Interventions

- **DRUG:** Brigatinib

## Key facts

- **NCT ID:** NCT03410108
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-29
- **Primary completion:** 2020-09-29
- **Final completion:** 2021-07-28
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410108, "Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03410108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*